Earlier this month Cypralis attended the Biotech and Money World Congress, a two-day event of workshops, discussions, and presentations to prospective investors. Whilst there Simon Kerr, Cypralis CEO, presented to investors and fellow biotech professionals as part of the Investable stream.

Cypralis has previously raised £4M investment and is looking for a further £8M in 2018 to continue research into novel, selective cyclophilin inhibitors. This would lead to the development of a series of clinical candidates for fibrosis, neurodegeneration and IO applications from the current library of >1800 novel drug-like inhibitors, exhibiting sub-type selectivity and excellent PK properties. Simon discussed the combined strategy of in house development and external partnerships, and future investment plans for Cypralis. 



Watch Simon's full presentation below.